课题基金 / 基金详情

项目摘要

项目成果

Paula M Cannon的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Despite the success of current anti-HIV drugs, which can often reduce levels of virus in a patient to undetectable levels, the drugs do not cure people of HIV, so that virus levels rapidly rebound if a patient stops taking the drugs. The major reason for this failure is that low levels of latent or reservoir HIV remain despite the drug treatment, hiding out in long-lived and quiescent cells such as central memory T cells. Strategies that removed this residual reservoir could complement current antiretroviral therapies and allow for the eventually cure of infected individuals. Here, we describe an approach to reduce the latent reservoir through the targeted delivery of HIV-specific nucleases to a key subset of cells that has been shown to be enriched in latent HIV genomes. The approach uses emerging technologies based on targeted nucleases and engineered viral vectors, and will be evaluated using in vivo models of HIV latency. In this way we propose to develop a new class of therapeutics that could contribute to the management of HIV infection and the goal of a cure.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nuclear receptor regulation of epigenetic mechanisms regulating HIV CNS latency
  • 批准号:
    10747002
  • 项目类别:
  • 资助金额:
    $74.52万
  • 财政年份:
    2023
  • 负责人:
    Paula M Cannon
  • 依托单位:
Gene edited B cells to co-express CNS-targeted antibodies
Gene edited B cells to co-express CNS-targeted antibodies
Combination gene editing for local and systemic HIV resistance
海外基金